---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-036614"
form_type: "8-K"
ticker: "TMDX"
cik: "0001756262"
company_name: "TransMedics Group, Inc."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T09:35:00.891553+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# TransMedics Q3 revenue $25.7M (+378% YoY); 2022 guidance raised to $80-85M

## Summary
- Net revenue $25.7M including $1.4M favorable adjustment; ex-adjustment $24.3M (+349% YoY).
- Full-year 2022 revenue guidance raised to $80-85M (ex-adjustment) vs prior $67-75M.
- Net loss narrowed to $7.4M from $13.0M in Q3 2021; cash and equivalents $204.5M.
- National OCS Program (NOP) drove ~90% of US revenue; public offering netted ~$140M.
- Gross margin 71% vs 70% a year ago; operating expenses $23.7M, up from $15.5M.

## SEC filing metadata
- accession: 0001564590-22-036614
- form_type: 8-K
- ticker: TMDX
- cik: 0001756262
- company_name: TransMedics Group, Inc.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1756262/000156459022036614/0001564590-22-036614-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1756262/000156459022036614/tmdx-8k_20221103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-036614
- JSON: https://secwatch.observer/filing/0001564590-22-036614.json
- Plain text: https://secwatch.observer/filing/0001564590-22-036614.txt

## Key facts
- Earnings Releases
  TransMedics Group, Inc. reported full year 2022 results: revenue $80 million to $85 million. Guidance raised.
  - Period: full year 2022
  - Revenue: $80 million to $85 million
  - Guidance: raised
  - Result: guidance update
  source text: TransMedics is updating full year 2022 revenue to be in the range of $80 million to $85 million, excluding the $1.4 million favorable change in estimate for contra revenue, which represents 164% to 181% growth compared to the company’s prior year revenue.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1756262/000156459022036614/0001564590-22-036614-index.htm
- Earnings Releases
  TransMedics Group, Inc. reported the quarter ended September 30, 2022 results: revenue $25.7 million, net income $7.4 million.
  - Period: the quarter ended September 30, 2022
  - Revenue: $25.7 million
  - Net income: $7.4 million
  - Result: reported results
  source text: Net revenue for the third quarter of 2022 was $25.7 million, a 378% increase compared to $5.4 million in the third quarter of 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1756262/000156459022036614/0001564590-22-036614-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.